Hatch BioFund Announces New Partnership with Brandywine Realty Trust <<more here>>

About Phillip S. Low, PhD

Philip S. Low, Ph.D.

Distinguished Professor of Chemistry-Biochemistry at Purdue University. 

Phillip Low







Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.  Dr. Low has spent more than 45 years doing pioneering work in the fields of tissue regeneration, infectious diseases, erythrocyte membranes and auto-immune diseases.  He has published more than 400 articles and has 75 patents/patents pending. Dr. Low is the co-founder of three RBP portfolio companies: Novosteo, Eradivir, and MorphImmune.

“So much of science is serendipity. You begin work with one specific goal in mind and then have an accidental finding or unexpected result that takes your work in a new, previously unimagined direction,” Philip Low says. “This kind of science thrives when you have a large collaborative scientific environment, like we have at Purdue Center for Cancer Research.”

“One of the most exciting avenues of cancer treatment that I’ve been pursuing is to develop methods to target drugs specifically to cancer cells and thereby avoid the collateral toxicity that normally occurs to healthy cells. In my lab, we’ve discovered that cancer cells have a much larger appetite than normal cells for the vitamin folic acid,” he says. “We’ve exploited this avarice for folic acid to deliver chemotherapy selectively to cancer cells by linking the vitamin to a cancer drug that can kill the malignant cell. We then allow the cancer to ‘eat’ the vitamin with its attached poison, using folic acid much like a Trojan horse to fool the cancer cell into internalizing a drug that will kill it.

“Right now, there are six drugs that are undergoing human clinical trials for kidney, ovarian, lung and endometrial cancers, resulting either directly or indirectly from research my lab has done here at Purdue,” Low says.